Indeed, our results demonstrate that the co-expression of CMTM6 or CMTM4 with PD-L1 on the membrane of tumor cells is critical for immunotherapeutic response and the pathological patterns of their expression may provide detailed information to conduct personalized immunotherapy. Here, CMTM4 is linked to neoplasm.